CN113999874B - Construction method and application of PHB1 gene knock-out non-human animal - Google Patents
Construction method and application of PHB1 gene knock-out non-human animal Download PDFInfo
- Publication number
- CN113999874B CN113999874B CN202111663104.7A CN202111663104A CN113999874B CN 113999874 B CN113999874 B CN 113999874B CN 202111663104 A CN202111663104 A CN 202111663104A CN 113999874 B CN113999874 B CN 113999874B
- Authority
- CN
- China
- Prior art keywords
- phb1
- human animal
- sequence
- gene
- sgrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150056105 PHB1 gene Proteins 0.000 title claims abstract description 93
- 238000003209 gene knockout Methods 0.000 title claims abstract description 46
- 238000010276 construction Methods 0.000 title claims abstract description 33
- 210000002987 choroid plexus Anatomy 0.000 claims abstract description 50
- 101001129610 Homo sapiens Prohibitin 1 Proteins 0.000 claims abstract description 38
- 102100031169 Prohibitin 1 Human genes 0.000 claims abstract description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 239000003440 toxic substance Substances 0.000 claims abstract description 10
- 229910001385 heavy metal Inorganic materials 0.000 claims abstract description 6
- 231100000614 poison Toxicity 0.000 claims abstract description 5
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 83
- 239000013598 vector Substances 0.000 claims description 70
- 230000008685 targeting Effects 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 230000006798 recombination Effects 0.000 claims description 31
- 238000005215 recombination Methods 0.000 claims description 31
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 20
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 230000013011 mating Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 108010051219 Cre recombinase Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108010091086 Recombinases Proteins 0.000 claims description 7
- 102000018120 Recombinases Human genes 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 108700024394 Exon Proteins 0.000 claims description 6
- 108010046276 FLP recombinase Proteins 0.000 claims description 6
- 230000002110 toxicologic effect Effects 0.000 claims description 2
- 231100000759 toxicological effect Toxicity 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 abstract description 28
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 10
- 238000012216 screening Methods 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 6
- 231100000027 toxicology Toxicity 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 4
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 241000700159 Rattus Species 0.000 description 117
- 108020004414 DNA Proteins 0.000 description 64
- 210000001519 tissue Anatomy 0.000 description 35
- 108091034117 Oligonucleotide Proteins 0.000 description 33
- 238000001514 detection method Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 239000012634 fragment Substances 0.000 description 14
- 235000013601 eggs Nutrition 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 7
- 238000001976 enzyme digestion Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002194 synthesizing effect Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 231100000167 toxic agent Toxicity 0.000 description 5
- 101150111131 Adgra3 gene Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 4
- 101100269402 Mus musculus Adgra3 gene Proteins 0.000 description 4
- 101100243770 Rattus norvegicus Phb1 gene Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000008844 regulatory mechanism Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 241000699729 Muridae Species 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000699725 Acomys Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 241000121210 Sigmodontinae Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001728 clone cell Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- -1 drugs and the like) Chemical class 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000007363 regulatory process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
- 206010009719 CNS ventriculitis Diseases 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 101100243764 Caenorhabditis elegans phb-1 gene Proteins 0.000 description 1
- 241000700193 Calomyscus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 101100311938 Dictyostelium discoideum phesA gene Proteins 0.000 description 1
- 101100423325 Dictyostelium discoideum phesB gene Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102100027280 Fanconi anemia group A protein Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101000914673 Homo sapiens Fanconi anemia group A protein Proteins 0.000 description 1
- 101001129654 Homo sapiens Prohibitin-2 Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102220470475 L-seryl-tRNA(Sec) kinase_C57L_mutation Human genes 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699669 Mus saxicola Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 101100247316 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ras-1 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100031156 Prohibitin-2 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 101150102092 ccdB gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 208000014106 choroid plexus cyst Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 108091007999 druggable proteins Proteins 0.000 description 1
- 102000038037 druggable proteins Human genes 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003059 ependyma Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108010072285 growth inhibitory proteins Proteins 0.000 description 1
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 101150080777 pheS gene Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011824 transgenic rat model Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a construction method of a PHB1 gene knock-out non-human animal and application thereof in the field of toxicology and biological medicine, wherein a Cre/LoxP and CRISPR/Cas9 system is utilized to obtain the non-human animal, the PHB1 protein which is not expressed or expressed in PHB1 protein in choroid plexus tissues of the non-human animal has no function, can be used as an animal model for screening obesity, diabetes, choroid plexus related diseases, tumors or inflammatory drugs and researching the choroid plexus toxicology by heavy metals or other toxic substances, and has important application value for researching and developing the obesity, the diabetes, the choroid plexus related diseases, the tumors or the inflammatory drugs.
Description
Technical Field
The application relates to a construction method and application of a gene-knocked non-human animal, in particular to a construction method based on PHB1 gene brain-knocked non-human animal and application thereof in the fields of toxicology and biomedicine.
Background
Choroid Plexus (CP) is formed by the division of the ependyma into the ventricles of the brain after invagination, and is arranged in a net shape in the ventricles of the brain, and can be divided into three types, namely, a lateral ventricular choroid plexus, a third ventricular choroid plexus and a fourth ventricular choroid plexus according to different anatomical locations. The choroid plexus is not only an important source of cerebrospinal fluid (CSF), but also can selectively transport some blood-borne substances into CSF through the blood-cerebrospinal fluid barrier (BCB) formed by its active epithelium, so as to maintain the homeostasis of CSF environment, while also preventing possible damage to brain tissue by some harmful factors present in the peripheral circulation.
In the toxic action and pharmacological action of exogenous substances, the choroid plexus has double characteristics, namely the nerve protection effect (preventing toxicant from entering brain tissues and cerebrospinal fluid); and some target tissues of neurotoxins (as sites of toxicant accumulation; or the toxic effects of exogenous substances can directly lead to structural and functional impairment of BCB). From the perspective of neuroprotection, the choroid plexus has a large number of microvilli and specific functional protein receptors/transporters, can selectively and actively absorb or discharge some specific substances, can be used as storage sites for some toxic heavy metals (such as compounds of lead, mercury, cadmium and the like) and other exogenous compounds (such as drugs and the like), shields and concentrates the toxic heavy metals and toxic substances in choroid plexus tissues, prevents the toxic heavy metals and toxic substances from entering cerebrospinal fluid, keeps the stability of cerebrospinal fluid components, and further plays a role in protecting the central nervous system.
The choroid plexus also plays an important role in the development, maturation, aging process, endocrine regulation of the brain, and the pathogenesis of some neurodegenerative diseases. In addition, studies of choroid plexus in brain tissue inflammation, aging, and secondary neurotoxic mechanisms have been reported. However, domestic studies on these aspects are limited, and focus mainly on choroid plexus cysts and tumors, and further emphasis has not been placed on study of choroid plexus-related toxicology and pharmacology. Through systematic research on the reaction mechanism of BCB under the action of internal and external compounds, the action exerted in the process of repairing nerve injury and after injury, the regulation mechanism and the like, it is possible to discover some nerve toxicants \ early diagnosis markers of nerve injury, transport proteins of CNS (central nervous system) specific drugs and the like, and promote the development of the diagnosis and treatment level of CNS diseases.
Inhibin protein (PHB 1) is composed of 275 amino acids, and is a protein which is highly conserved in structure and widely distributed in mitochondria of eukaryotes and has various functions. It is mainly involved in maintaining mitochondrial structure and function, protecting cells against aging, regulating intracellular iron homeostasis, and participating in mitochondrial protein stabilization and mitochondrial structure maintenance as a chaperone protein. Furthermore, the distribution of PHB1 in the nucleus and cytoplasm makes it involved in cell cycle, apoptosis and transcriptional regulation, and as a cell surface receptor in intracellular signal transduction. The expression change of PHB1 directly affects the increase of oxidative stress and the dysfunction and structural abnormality of mitochondria, which is closely related to the induction of certain diseases such as cancer, inflammatory diseases, insulin resistance type 2 diabetes and the like and the drug treatment of chronic diseases.
The role of PHB1 in mitochondria is the most deeply and clearly researched at present, PHB1 and PHB2 are combined with each other to form foreign body dimers, each 12-16 foreign body dimers are further polymerized to form concentric circular ground-like structures, and are anchored on the inner membrane of mitochondria through the common amino-terminal lipophilic domain of the foreign body dimers, play the role of molecular chaperone protein, maintain the sum function of mitochondria, and serve as iron storage protein in mitochondria to maintain the iron dynamic balance in vivo and participate in anti-apoptosis.
In recent years, it has been found through immunohistochemistry and co-immunoprecipitation that PHB1 colocalizes with other tumor growth inhibitory proteins such as E2F transcription factor family member, Rb protein family member, p53 tumor inhibitory protein and the like in the nucleus of the cell in breast cancer cell lines and prostate cell lines, and exerts cell proliferation inhibition and pro-apoptosis effects through their respective interactions. This is also the reason why PHB1 is gaining attention as a target protein for the research of antitumor drugs.
Krishnaraaj and Thomas established PHB1 gene silencing cell line by siRNA technology in 2005, found another role of PHB1 protein, namely Ras activation and Ras-1 binding, which are involved as chaperones of Raf-1 on plasma membrane and anchoring firmly to plasma membrane, occurred a series of phosphorylation processes, such as tyrosine 341 and Serine 338 (tyrosine 341, Serine 338), dephosphorylation (Serine 259), dimerization reaction, etc. to further activate Raf-1, and exerted the role of regulating processes of cell proliferation, differentiation, cell death, mitosis, migration, inflammation, etc. by phosphorylating MEK protein kinase, ERK kinase (the Serine/thionine specific extracellular signal-regulated kinase, ERK) and MAPK kinase (mitogen-activated protein kinase, MAPK).
In addition to its cell cycle regulating effect, PHB1 has multiple functions, and its different localization and differential expression in various diseases suggest that PHB1 may be involved in the process of disease development and progression. Currently, PHB1 is considered as a potential biomarker index for evaluating the course of disease progression and disease risk prediction of diseases such as liver injury, nasopharyngeal carcinoma and the like, and is used as a new drug target protein for treating diseases such as tumor, obesity, diabetes and the like.
Previous studies have demonstrated that: manganese (6 mg/kg. BW) has pathological damage effect on rat choroid plexus tissue and can cause the expression of PHB1 protein in the choroid plexus tissue to be up-regulated; in vitro studies, under the action of manganese, the choroid plexus epithelial cell line Z310 generates cell cycle block and the expression of PHB1 protein is up-regulated, and the molecular regulation mechanism of PHB1 is combined to conclude that the cell cycle block plays an important regulation role in Z310 cell cycle block caused by manganese, but the exact regulation mechanism is not clear.
Based on the research results and problems and a conditional gene knockout Cre/loxP recombination system, a CRISPR/Cas9 system is applied, a LoxP gene is inserted into introns at the 5 'end and the 3' end of a rat PHB1 gene in a fixed point mode, then the gene sequence constructed in vitro is transferred into a fertilized egg, the fertilized egg replaces the original gene sequence in a cell genome through homologous recombination, the fertilized egg is implanted into the uterus of a pseudopregnant rat to be regenerated into a complete embryo, finally, a transgenic rat with loxP sites in introns at two sides of a target gene is formed, the Adgra3-CreERT2 gene is knocked into the rat to be hybridized with the rat, and then the PHB1 gene brain choroid plexus tissue conditional knockout rat can be screened out from offspring. The conditional knockdown of the PHB1 gene by a non-human animal construction is helpful for verifying and mining a definite molecular regulation mechanism of PHB1 in the apoptosis and cycle block effects of manganese-induced choroid plexus tissue epithelial cells from the whole animal level, and how the consequences of the manganese-induced choroid plexus epithelial cell cycle block regulated by PHB1 influence the secretion function of choroid plexus, influence the synthesis and secretion of dopamine neuron-specific neurotrophic factor GDF-15 and influence the damage repair of dopamine neurons finally, so that the development of a non-human animal model for the PHB1 gene is urgently needed in the art.
Non-patent document "Liver-specific deletion of suppression 1 residues in specific Liver deficiency in jury, fibrosis, and hepatocellular cancer in mice" Hepatology, 2010, 52(6): 2096-.
Therefore, the prior art discloses only liver PHB1 gene knockout mice for liver studies, but does not disclose choroid plexus PHB1 gene knockout non-human animals, and does not disclose PHB1 gene knockout non-human animals constructed using a combination of Cre/loxP recombination system and CRISPR/Cas9 system.
Disclosure of Invention
The invention relates to a PHB1 gene knock-out construction method of a non-human animal, which comprises knocking out a PHB1 gene, so that the PHB1 protein in choroid plexus tissues of the non-human animal is not expressed or the expressed PHB1 protein does not have functions. Preferably, the coding sequence of the PHB1 gene, the genomic DNA sequence, the sequence controlling expression of the PHB1 protein, or the functional region of the PHB1 protein is knocked out.
Preferably, the choroid plexus tissue includes, but is not limited to, epithelial tissue and connective tissue, including, but not limited to, epithelial cells, ependymal cells, macrophages, and the like.
Wherein, the coding sequence of the knocked-out PHB1 gene comprises the coding sequence of exons 4 to 5 of the PHB1 gene.
The invention uses gene editing technology to carry out PHB1 gene knock-out unless the construction of human animal, the gene editing technology includes gene targeting technology using embryonic stem cell, CRISPR/Cas9 technology, zinc finger nuclease technology, transcription activator-like effector nuclease technology, homing endonuclease, RNAi technology, Cre/LoxP technology, Flp/Frt technology or other molecular biology technology or their combination. Further preferably, the gene editing technology utilizes a combination of CRISPR/Cas9 technology and/or Cre/loxP technology.
Preferably, a homologous specific recombination site recognition sequence is inserted into a non-human animal PHB1 locus to obtain a conditional PHB1 gene knockout Flox non-human animal, a recombinase or a recombinase expression sequence is introduced into the conditional PHB1 gene knockout Flox non-human animal, and the conditional PHB1 gene knockout Flox non-human animal PHB1 gene is deleted to obtain a PHB1 gene knockout non-human animal.
Further preferably, the insertion sites are intron3 and intron 5.
Further preferably, the PHB1 gene knocks out exon4 to exon 5.
Further preferably, the homologated specific recombination site recognition sequences include, but are not limited to LoxP or Frt.
Further preferably, the recombinase includes, but is not limited to Cre or Flp.
More preferably, a LoxP or Frt sequence is inserted into each of intron3 and intron5 of PHB1 gene of the non-human animal to obtain a conditional PHB1 gene knockout Flox non-human animal, the conditional PHB1 gene knockout Flox non-human animal is mated with a non-human animal expressing Cre or Flp recombinase in choroid plexus tissue, and the PHB1 gene knockout non-human animal is obtained by using a Cre-LoxP or Flp-Frt gene recombination system.
Preferably, the non-human animal expressing Cre or Flp recombinase in choroid plexus tissue is obtained by knocking a nucleotide sequence encoding Cre into a gene encoding a protein expressed from the tissue.
Further preferably, the nucleotide sequence encoding Cre can be a nucleotide sequence encoding Cre-ER and a sequence optimized from a protein perspective or a gene perspective, including but not limited to a nucleotide sequence encoding Cre-ERT, Cre-ERT2 or iCre-ERT 2.
Further preferably, the gene encoding the protein expressed from the tissues in the choroid is the Adgra3 gene. The knock-in position is preferably after the promoter, so that the knock-in Cre-encoding nucleotide sequence is under the control of the regulatory elements of the Adgra3 gene.
Preferably, the construction method comprises inserting a LoxP or Frt sequence into the PHB1 locus using sgRNA and/or targeting vectors.
Preferably, the sgRNA 3' end comprises a PAM sequence, and further preferably, the PAM sequence may be AGG, TGG or GGG.
Further preferably, the target site sequence at the 5 'end of the sgRNA target is shown in any one of SEQ ID No.1-7, and the target site sequence at the 3' end of the sgRNA target is shown in any one of SEQ ID No. 8-14.
Still more preferably, the sequence of the target site at the 5 'end of the sgRNA target is shown in SEQ ID No.5, and the sequence of the target site at the 3' end of the sgRNA target is shown in SEQ ID No. 8.
Preferably, the bottom strand oligonucleotide of the sgRNA has more than 80% homology with any one of SEQ ID nos. 15 to 28 or comprises a nucleotide sequence set forth in any one of SEQ ID nos. 15 to 28.
Further preferably, the targeting vector comprises a5 'arm, a 3' arm and a donor DNA sequence, wherein the donor DNA sequence comprises a homonymous specific recombination site recognition sequence, a PHB1 gene nucleotide sequence and a homonymous specific recombination site recognition sequence from 5 'to 3'.
Still more preferably, the nucleotide sequence of PHB1 gene comprises exon4 to exon 5 of PHB1 gene.
Still more preferably, the 5' arm is as shown in SEQ ID NO. 51.
Still more preferably, the 3' arm is as shown in SEQ ID NO. 52.
Still more preferably, the homotropic specific recombination site recognition sequence is LoxP or Frt. The non-human animal of the invention is selected from rodent, pig, chicken, rabbit, monkey and any other non-human animal which can be subjected to gene editing to prepare gene humanization.
Preferably, the non-human animal is a non-human mammal, more preferably, the non-human mammal is a rodent, and even more preferably, the rodent is a rat or a mouse.
In a specific embodiment of the invention, the construction method comprises the steps of introducing a targeting vector, sgRNA targeting PHB1 gene and Cas9 into a non-human animal cell, culturing the cell (preferably an embryonic stem cell), transplanting the cultured cell into an oviduct of a female non-human animal, allowing the cell to develop, hybridizing offspring with the non-human animal expressing Cre or Flp recombinase, and identifying and screening to obtain the PHB1 gene knock-out non-human animal.
Preferably, the construction method comprises the following steps:
1) preparing a forward oligonucleotide sequence and a reverse oligonucleotide sequence from any one or more sgRNA target sequences with sequences shown as SEQ ID NO. 1-14;
2) synthesizing fragment DNA containing a T7 promoter and sgRNA scaffold, sequentially carrying out enzyme digestion on the fragments to be connected to a framework vector, and carrying out sequencing verification to obtain a pT7-sgRNA vector;
3) respectively synthesizing the forward oligonucleotide and the reverse oligonucleotide in the step 1), and denaturing and annealing the synthesized sgRNA oligonucleotides to form a double strand which can be connected into the pT7-sgRNA vector in the step 2);
4) respectively linking the double-stranded sgRNA oligonucleotides annealed in the step 3) with pT7-sgRNA vectors, and screening to obtain sgRNA vectors.
5) Designing a targeting vector, and constructing and obtaining the targeting vector containing a LoxP/Frt recombination system, wherein the targeting vector contains a PHB1 gene homologous sequence, 2 LoxP/Frt sequences, a3 'arm and a 5' arm;
6) mixing an in-vitro transcription product of the sgRNA vector, Cas9 mRNA and a targeting vector to obtain a mixed solution, injecting the mixed solution into cytoplasm or nucleus of a fertilized egg of the non-human animal, transferring the fertilized egg after injection into a culture solution for culture, and then transplanting the fertilized egg into an oviduct of the non-human animal of a receptor parent for development to obtain an F0 generation non-human animal;
7) checking the F0 generation non-human animal by using a PCR technology, verifying the introduction condition of the targeting vector, and obtaining a positive non-human animal introduced with the targeting vector;
8) crossing the positive non-human animal screened in the step 7) with a non-human animal expressing Cre or Flp recombinase to establish a stable PHB1 gene knock-out non-human animal.
In a second aspect, the present invention relates to a PHB1 gene knock-out non-human animal or its progeny, which is obtained by the above-described construction method.
The third aspect of the invention relates to a construction method of a conditional PHB1 gene knockout Flox non-human animal, wherein a homodromous specific recombination site recognition sequence is inserted into a PHB1 gene locus of the non-human animal.
Preferably, the homologous specific recombination site recognition sequences include, but are not limited to LoxP or Frt.
Preferably, the insertion sites are intron3 and intron5 of PHB1 gene.
In a specific embodiment of the invention, the construction method comprises the step of inserting a LoxP or Frt sequence into an intron3 and an intron5 of a PHB1 gene of a non-human animal respectively to obtain a conditional PHB1 gene knockout Flox non-human animal.
Preferably, the PHB1 gene knocks out exons 4 to 5.
Preferably, the construction method comprises inserting a LoxP or Frt sequence into the PHB1 locus using sgRNA and/or targeting vectors.
Preferably, the sgRNA 3' end comprises a PAM sequence, and further preferably, the PAM sequence may be AGG, TGG or GGG.
Further preferably, the target site sequence at the 5 'end of the sgRNA target is shown in any one of SEQ ID No.1-7, and the target site sequence at the 3' end of the sgRNA target is shown in any one of SEQ ID No. 8-14.
Still more preferably, the sequence of the target site at the 5 'end of the sgRNA target is shown in SEQ ID No.5, and the sequence of the target site at the 3' end of the sgRNA target is shown in SEQ ID No. 8.
Preferably, the bottom strand oligonucleotide of the sgRNA has more than 80% homology with any one of SEQ ID nos. 15 to 28 or comprises a nucleotide sequence set forth in any one of SEQ ID nos. 15 to 28.
Further preferably, the targeting vector comprises a5 'arm, a 3' arm and a donor DNA sequence, wherein the donor DNA sequence comprises a homonymous specific recombination site recognition sequence, a PHB1 gene nucleotide sequence and a homonymous specific recombination site recognition sequence from 5 'to 3'.
Still more preferably, the nucleotide sequence of PHB1 gene comprises exon4 to exon 5 of PHB1 gene.
Still more preferably, the 5' arm is as shown in SEQ ID NO. 51.
Still more preferably, the 3' arm is as shown in SEQ ID NO. 52.
Still more preferably, the homotropic specific recombination site recognition sequence is LoxP or Frt.
The non-human animal of the invention is selected from rodent, pig, chicken, rabbit, monkey and any other non-human animal which can be subjected to gene editing to prepare gene humanization.
Preferably, the non-human animal is a non-human mammal, more preferably, the non-human mammal is a rodent, and even more preferably, the rodent is a rat or a mouse.
In one embodiment of the present invention, the construction method comprises the following steps: constructing a vector for generating the sgRNA and obtaining an sgRNA in-vitro transcription product, constructing a targeting vector containing an exogenous nucleotide sequence, introducing the sgRNA in-vitro transcription product, Cas9 mRNA and the targeting vector into a non-human animal cell, and further implanting into the uterus of a pseudopregnant mother mouse to obtain a non-human animal or a progeny thereof. The non-human animal cell may be a fertilized egg cell, an ES cell or a somatic cell of a non-human animal.
Preferably, the construction method comprises the following steps:
1) preparing a forward oligonucleotide sequence and a reverse oligonucleotide sequence from any one or more sgRNA target sequences with sequences shown as SEQ ID NO. 1-14;
2) synthesizing fragment DNA containing a T7 promoter and sgRNA scaffold, sequentially carrying out enzyme digestion on the fragments to be connected to a framework vector, and carrying out sequencing verification to obtain a pT7-sgRNA vector;
3) respectively synthesizing the forward oligonucleotide and the reverse oligonucleotide in the step 1), and denaturing and annealing the synthesized sgRNA oligonucleotides to form a double strand which can be connected into the pT7-sgRNA vector in the step 2);
4) respectively linking the double-stranded sgRNA oligonucleotides annealed in the step 3) with pT7-sgRNA vectors, and screening to obtain sgRNA vectors.
5) Designing a targeting vector, and constructing and obtaining the targeting vector containing a LoxP/Frt recombination system, wherein the targeting vector contains a PHB1 gene homologous sequence, 2 LoxP/Frt sequences, a3 'arm and a 5' arm;
6) mixing an in-vitro transcription product of the sgRNA vector, Cas9 mRNA and a targeting vector to obtain a mixed solution, injecting the mixed solution into cytoplasm or nucleus of a fertilized egg of the non-human animal, transferring the fertilized egg after injection into a culture solution for culture, and then transplanting the fertilized egg into an oviduct of the non-human animal of a receptor parent for development to obtain an F0 generation non-human animal;
7) and (3) checking the F0 generation non-human animal by using a PCR technology, verifying the introduction condition of the targeting vector, and obtaining a positive non-human animal of the introduction targeting vector, namely the conditional PHB1 gene knockout Flox non-human animal.
The third method of the invention relates to a conditional PHB1 gene knockout Flox non-human animal obtained by adopting the construction method.
In a fourth aspect, the invention relates to a conditional PHB1 gene knockout, Flox, non-human animal as described above for use in knocking in the PHB1 gene of a non-human animal.
The fifth aspect of the invention relates to a sgRNA targeting a PHB1 gene, wherein a target site sequence at the 5 'end of the sgRNA targeting is shown in any one of SEQ ID No.1-7, and a target site sequence at the 3' end of the sgRNA targeting is shown in any one of SEQ ID No. 8-14.
Still more preferably, the sequence of the target site at the 5 'end of the sgRNA target is shown in SEQ ID No.5, and the sequence of the target site at the 3' end of the sgRNA target is shown in SEQ ID No. 8.
Preferably, the bottom strand oligonucleotide sequence of the sgRNA has more than 80% homology with any one of SEQ ID nos. 15 to 28 or comprises the nucleotide sequence set forth in any one of SEQ ID nos. 15 to 28.
In a sixth aspect, the present invention relates to a vector comprising the sgRNA described above. Preferably, the vector comprises a T7 promoter and a fragment DNA of sgrnascfold.
Preferably, the vector is a viral vector, such as a lentivirus, retrovirus, adenovirus, herpes simplex virus, and the like.
The seventh aspect of the invention relates to a targeting vector, which comprises a5 'arm, a 3' arm and a donor DNA sequence, wherein the donor DNA sequence comprises a homonymous specific recombination site recognition sequence, a PHB1 gene nucleotide sequence and a homonymous specific recombination site recognition sequence from 5 'to 3'.
Preferably, the nucleotide sequence of the PHB1 gene comprises exons 4 to 5 of the PHB1 gene.
Preferably, the 5' arm is shown in SEQ ID NO. 51.
Preferably, the 3' arm is shown in SEQ ID NO. 52.
Preferably, the homotropic specific recombination site recognition sequence is LoxP or Frt.
Preferably, the targeting vector further comprises a marker gene, more preferably, the marker gene is a gene encoding a negative selection marker, and even more preferably, the gene encoding the negative selection marker may be a gene encoding diphtheria toxin subunit A (DTA), herpes simplex virus thymidine kinase (HSV-tk), SacB, rpsl (strA), tetAR, pheS, thy, CaCY, gata-I, ccdB, or the like.
In one embodiment of the present invention, the targeting vector further comprises a resistance gene selected from a positive clone, and more preferably, the resistance gene selected from the positive clone can be neomycin phosphotransferase coding sequence Neo, hygromycin B phosphotransferase (hph), xanthine/guanine phosphotransferase (gpt), hypoxanthine phosphotransferase (Hprt), thymidine kinase (tk), and puromycin acetyltransferase (puro).
An eighth aspect of the present invention relates to a method for preparing a vector for sgRNA, including the steps of:
1) preparing a forward oligonucleotide sequence and a reverse oligonucleotide sequence from any sgRNA target sequence with a sequence shown in SEQ ID NO. 1-14;
2) synthesizing fragment DNA containing a T7 promoter and sgRNA scaffold, sequentially carrying out enzyme digestion on the fragments to be connected to a framework vector, and carrying out sequencing verification to obtain a pT7-sgRNA vector;
3) respectively synthesizing the forward oligonucleotide and the reverse oligonucleotide in the step 1), and denaturing and annealing the synthesized sgRNA oligonucleotides to form a double strand which can be connected into the pT7-sgRNA vector in the step 2);
4) respectively linking the double-stranded sgRNA oligonucleotides annealed in the step 3) with pT7-sgRNA vectors, and screening to obtain sgRNA vectors.
In a ninth aspect, the present invention relates to a DNA molecule encoding the sgRNA described above.
A tenth aspect of the present invention relates to a cell containing the targeting vector, the sgRNA targeting PHB1 gene, the vector containing the sgRNA, or the DNA molecule.
An eleventh aspect of the present invention relates to a sgRNA that includes the targeting vector, the targeted PHB1 gene, the vector including the sgRNA, the DNA molecule, or the cell, and uses thereof for PHB1 gene knock-out.
In a twelfth aspect, the invention relates to an animal disease model, wherein the disease model is derived from the non-human animal or its offspring, and the non-human animal obtained by the above construction method or its offspring. Preferably, the disease comprises obesity, diabetes, choroid plexus related diseases, tumors or inflammation. Such as tumor-bearing animal models.
In a thirteenth aspect of the present invention, there is provided a method for preparing a disease model of an animal, said method comprising the steps of constructing the above non-human animal; preferably, the disease comprises obesity, diabetes, choroid plexus related diseases, tumors or inflammation, and further preferably, the step of implanting tumor cells is included.
In a fourteenth aspect of the present invention, there is provided a use of the sgRNA, the vector comprising the sgRNA, the DNA molecule, the targeting vector, the non-human animal or its progeny, or the non-human animal or its progeny obtained by the above-described construction method, for preparing a disease model of an animal, preferably, the disease includes obesity, diabetes, choroid plexus-related diseases, tumors, or inflammation.
In a fifteenth aspect of the present invention, the sgRNA, the vector comprising the sgRNA, the DNA molecule, the targeting vector, the non-human animal or its progeny, the non-human animal obtained by the above construction method or its progeny, or the disease model described above are provided for use in studying the toxicological effects of heavy metals or other toxic substances on the choroid plexus of the brain and in preparing a medicament for treating obesity, diabetes, choroid plexus-related diseases, tumors, and/or inflammation.
In a sixteenth aspect, the present invention relates to a cell, tissue or organ derived from the above-mentioned non-human animal or progeny thereof, or a disease model.
The seventeenth aspect of the present invention relates to an application of the above non-human animal or its progeny, the non-human animal obtained by the above construction method or its progeny, and the above cell, tissue or organ in the preparation of a medicament for treating or preventing obesity, diabetes, choroid plexus-related diseases, tumors or inflammation.
The eighteenth aspect of the present invention relates to an application of the above non-human animal or its progeny, the non-human animal obtained by the above construction method or its progeny, and the above cell, tissue or organ in research related to PHB1 gene or protein, wherein the application comprises:
A) to applications in the development of products involving cell cycle regulation;
B) as model systems for toxicology, pharmacology, immunology, microbiology and medical research;
C) relates to the production of cell cycle regulatory processes and the use of animal experimental disease models for the application in the aetiology, toxicology studies, for the development of diagnostic strategies or for the development of therapeutic strategies;
D) screening, drug effect detection, curative effect evaluation, verification or evaluation of PHB1 signal channel regulator in vivo; or,
E) research on PHB1 gene or protein function, research on medicine and drug effect aiming at PHB1 target site, and research on application of medicines for treating obesity, diabetes, choroid plexus related diseases, and tumor or inflammation.
The "choroid plexus-related disorders" described herein include, but are not limited to, choroidal cysts, choroidal enlargement, choroidal papillomas, meningiomas, ventriculitis, plexitis, Sturge-Weber syndrome, or neurofibromatosis.
The "tumor" according to the present invention includes, but is not limited to, lymphoma, brain cancer, non-small cell lung cancer, cervical cancer, esophageal cancer, leukemia, ovarian cancer, nasopharyngeal cancer, breast cancer, endometrial cancer, colon cancer, rectal cancer, stomach cancer, bladder cancer, lung cancer, bronchial cancer, bone cancer, prostate cancer, pancreatic cancer, liver and bile duct cancer, esophageal cancer, kidney cancer, thyroid cancer, head and neck cancer, testicular cancer, glioblastoma, astrocytoma, melanoma, myelodysplastic syndrome, and sarcoma. Wherein the leukemia is selected from acute lymphocytic (lymphoblastic) leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, multiple myeloma, plasma cell leukemia, and chronic myelogenous leukemia; said lymphoma is selected from Hodgkin's lymphoma and non-Hodgkin's lymphoma, including B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, T-cell lymphoma, and Waldenstrom's macroglobulinemia; the sarcoma is selected from osteosarcoma, Ewing's sarcoma, leiomyosarcoma, synovial sarcoma, soft tissue sarcoma, angiosarcoma, liposarcoma, fibrosarcoma, rhabdomyosarcoma, and chondrosarcoma.
The term "inflammation" as used herein includes acute inflammation as well as chronic inflammation. Specifically, it includes, but is not limited to, degenerative inflammation, exudative inflammation (serous inflammation, cellulolytic inflammation, suppurative inflammation, hemorrhagic inflammation, necrotizing inflammation, catarrhal inflammation), proliferative inflammation, specific inflammation (tuberculosis, syphilis, leprosy, lymphogranuloma, etc.).
The term "treating" (or "treatment") as used herein means slowing, interrupting, arresting, controlling, stopping, alleviating, or reversing the progression or severity of one sign, symptom, disorder, condition, or disease, but does not necessarily refer to the complete elimination of all disease-related signs, symptoms, conditions, or disorders. The term "treatment" or the like refers to a therapeutic intervention that ameliorates the signs, symptoms, etc. of a disease or pathological state after the disease has begun to develop.
The term "homology" as used herein refers to the fact that, in the aspect of using an amino acid sequence or a nucleotide sequence, a person skilled in the art can adjust the sequence according to the actual working requirement, so that the used sequence has (including but not limited to) 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% identity.
One skilled in the art can determine and compare sequence elements or degrees of identity.
The Cre-ER disclosed by the invention is a fusion protein (Cre-ER) positioned in cytoplasm and formed by fusing a ligand binding region (LBD) of a human estrogen receptor (ER for short) with a Cre recombinase, wherein the fused Cre protein can be subjected to conformational change and dissociated from an anchoring protein HSP90 only after hormone induction, enters a cell nucleus, recognizes a loxP site and is subjected to cutting.
The Cre-ERT provided by the invention is obtained by performing point mutation (G521R) in a ligand binding region of ER, and only responding to exogenous artificially synthesized estrogen, such as Tamoxifen (Tamoxifen), to induce Cre-ERT.
The Cre-ERT2 of the invention is that on the basis of Cre-ERT, 3 point mutations are added in LBD of ER: C400V/M453A/L544A, and the obtained mutant is Cre-ERT 2. Cre-ERT2 is more sensitive to tamoxifen metabolite 4-OHT.
The invention relates to an iCre-ERT2, which is based on Cre-ERT2, further improves Cre recombinase and aims to improve expression in mammals and reduce the chance of epigenetic silencing, and concretely relates to Shimshek DR, et al Codon-improved Cre restriction enzyme (iCre) expression in the gene, Gene 2002.
In one aspect, the non-human animal is a mammal. In one aspect, the non-human animal is a small mammal, such as a rhabdoid. In one embodiment, the non-human animal is selected from the group consisting of a mouse, a rat, and a hamster. In one embodiment, the non-human animal is selected from the murine family. In one embodiment, the genetically modified animal is from the family of cricotidae (e.g., mouse-like hamsters), cricotidae (e.g., hamsters, new world rats and mice, voles), muridae (true mice and rats, gerbils, spiny mice, crow rats), marmoraceae (mountaineers, rock mice, tailed rats, madagaska rats and mice), spiny muridae (e.g., spiny mice), and spale (e.g., mole rats, bamboo rats, and zokors). In a particular embodiment, the genetically modified rodent is selected from a true mouse or rat (superfamily murinus), a gerbil, a spiny mouse, and a crowned rat. In one embodiment, the genetically modified mouse is from a member of the murine family. In one embodiment, the non-human animal is selected from a mouse and a rat. In one embodiment, the non-human animal is a rat.
In a particular embodiment, the non-human animal is a non-human mammal which is a mouse strain selected from the group consisting of BALB/C, A/He, A/J, A/WySN, AKR/A, AKR/J, AKR/N, TA1, TA2, RF, SWR, C3H, C57BR, SJL, C57L, DBA/2, KM, NIH, ICR, CFW, FACA, C57BL/A, C BL/An, C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6 6357 BL/6ByJ, C57BL/6NJ, C57BL/10, C57BL/10ScSn, C57BL/10 and C57BL/Ola, C57 36 BL, C58, Br, A/Ca, CBA/J, CBA/CBA, CBCBH/J, CBA, CBH.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology. These techniques are explained in detail in the following documents. For example: molecular Cloning A Laboratory Manual, 2nd Ed., ed. By Sambrook, FritschandManiatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (d.n. glovered., 1985); oligonucleotide Synthesis (m.j. gaited., 1984); mullisetal U.S. Pat. No.4, 683, 195; nucleic Acid Hybridization (B.D. Hames & S.J. Higgins.1984); transformation And transformation (B.D. Hames & S.J. Higgins.1984); culture Of Animal Cells (r.i. freshney, alanr.liss, inc., 1987); immobilized Cells And Enzymes (IRL Press, 1986); B.Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J.Abelson and M.Simon, eds., In-chief, Academic Press, Inc., New York), specific, volumes, 154 and 155 (Wuetal. eds.) and Vol.185, "Gene Expression Technology" (D.Goeddel, ed.); gene Transfer Vectors For Mammarian Cells (J.H.Miller and M.P.Caloseds, 1987, Cold Spring Harbor Laboratory); immunochemical Methods In Cell And Molecular Biology (Mayer And Walker, eds., Academic Press, London, 1987); handbook Of Experimental Immunology, Volumes V (d.m.weir and c.c.blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).
The term Wildtype allel (WT) as described in this invention: i.e. wild type rats;
the term Targeted allel (fl) as described herein: i.e., F1 generation positive heterozygous rats obtained by mating F0 generation mice and wild type rats.
The term Deleted allele (Δ) as described herein: that is, rats with the objective gene knocked out in a tissue-specific or whole body manner are obtained by mating fl rats with tissue-specific Cre or Cre-deleter rats.
The invention has the technical effects that the CRISPR/Cas9 and Cre/loxP two-major gene recombination system is applied to gene conditional knockout recombination, and the new view point of choroid plexus tissue is taken as a research target: choroid plexus tissues play an important role in brain development, maturation, aging processes, endocrine regulation, and pathogenesis of some neurodegenerative diseases. In the toxic action and pharmacological action of exogenous substances, the choroid plexus has double characteristics, namely the nerve protection effect (preventing toxicant from entering brain tissues and cerebrospinal fluid); and some target tissues of neurotoxins (as sites of toxicant accumulation; or the toxic effects of exogenous substances can directly lead to structural and functional impairment of BCB). And based on a certain research basis, the gene of the functional protein PHB1 is directly modified, so that the action mechanism of PHB1 in the toxicity generation process can be better discussed, and the conditional knock of the gene of the brain choroid plexus PHB1 is not established unless a human animal model is established at present.
The foregoing is merely a summary of aspects of the invention and is not, and should not be taken as, limiting the invention in any way.
All patents and publications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication was specifically and individually indicated to be incorporated herein by reference. Those skilled in the art will recognize that certain changes may be made to the invention without departing from the spirit or scope of the invention. The following examples further illustrate the invention in detail and are not to be construed as limiting the scope of the invention or the particular methods described herein.
Drawings
Embodiments of the invention are described in detail below with reference to the attached drawing figures, wherein:
FIG. 1: technical roadmap for conditional knock-out rats for the PHB1 gene;
FIG. 2: southern blot detection of the F1 mouse tail DNA;
FIG. 3: the detection result of the activity of the sgRNA1-sgRNA14, wherein Con is a negative control, and PC is a positive control;
FIG. 4: schematic diagram of targeting strategy;
FIG. 5: schematic representation of Southern blot screening strategy;
FIG. 6: the enzyme digestion and sequencing verification result shows that 1 uses restriction enzyme KpnI, the length of the target fragment is 4116bp +2973bp, 2 uses restriction enzyme EcoRI, and the length of the target fragment is 5519bp +1138bp +432 bp; 3, using restriction enzyme as XhoI, the length of the target fragment is 4085bp +3004bp, and ck is a control group;
FIG. 7: genotype test results of F0 rat, wherein M is Marker, WT is wild control, H2O is water control, A is (EGE-ZK-033) -L-GT-F/cKO-3'-DO-R primer detection result, B is cKO-5' -DO-F/(EGE-ZK-033) -R-GT-R primer detection result;
FIG. 8: f1 generation rat genotype test result, wherein M is Marker, WT is wild control, + is positive control, H2O is water control, A is (EGE-ZK-033) -L-GT-F/cKO-3'-DO-R primer detection result, B is cKO-5' -DO-F/(EGE-ZK-033) -R-GT-R primer detection result;
FIG. 9: obtaining a tissue-specific PHB1 gene knockout rat scheme, wherein WT is a wild type rat, fl is an F1 generation positive heterozygote rat obtained by mating an F0 generation rat and a wild type rat, and delta is a tissue-specific or whole-body knockout rat obtained by mating an fl rat and a tissue-specific Cre or Cre-deleter rat;
FIG. 10: conditional PHB1 gene knockout first step protocol genotype mapping (one);
FIG. 11: conditional PHB1 gene knockout first step protocol genotype mapping (two);
FIG. 12: conditional PHB1 Gene knockout the second protocol genotype mapping;
FIG. 13: obtaining a PHB1 full gene knockout rat scheme, wherein WT is a wild type rat, fl is an F1 generation positive heterozygote rat obtained by mating an F0 generation rat and a wild type rat, and delta is a tissue specificity or whole body knockout rat obtained by mating an fl rat and a tissue specificity Cre or Cre-deleter rat;
FIG. 14: PHB1 full knockout first step protocol genotype mapping;
FIG. 15: the second step of the whole gene knockout of PHB1 is a genotype map;
FIG. 16: schematic diagram of pCS-3G vector;
FIG. 17: RNA electrophoresis at 65 deg.C for 5 min.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are illustrative only and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Example 1 conditional PHB1 Gene knockout Flox rats
In order to knock out a PHB1 gene, a rat PHB1 gene is knocked out mainly through a Cre/loxP recombination system, LoxP is inserted into a rat PHB1 locus through a CRISPR/Cas9 system to obtain a conditional PHB1 gene knock-out Flox rat, a recombinase or a recombinase expression sequence is introduced into the conditional PHB1 gene knock-out Flox rat, a conditional PHB1 gene knock-out Flox animal PHB1 gene is deleted, so that the PHB1 protein in choroid plexus tissues is not expressed or the expressed PHB1 protein does not have functions, and the PHB1 gene knock-out rat is obtained, and the specific construction method is shown in figure 1.
Firstly, a CRISPR/Cas system is introduced for gene editing, and target sequences in the system determine the target specificity of sgRNAs and the efficiency of inducing Cas9 to cut target genes, but the gene sequences may be different in different strains. In order to ensure the efficiency of the designed CRISPR/sgRNA, the target site sequence of the tail of a rat needs to be subjected to PCR amplification and sequencing verification to ensure that the recognition sequence of the sgRNA is completely consistent with the DNA sequence of the rat of the constructed strain. The PCR primers are shown in Table 1.
Efficient and specific target sequence selection and design are the premise of constructing an sgRNA expression vector, and a sgRNA target site sequence (sgRNA 1-sgRNA 14) is designed and synthesized, wherein the target site sequence targeted by each sgRNA is shown in Table 2, and the bottom strand oligonucleotide sequence of each sgRNA is shown in Table 3. Oligos were synthesized according to the designed sgRNA sequence and ligated into the pCS-3G plasmid by Gibson seamless ligation as shown in FIG. 16, and the ligation products were transformed and then submitted to sequencing for correct sequencing.
Table 1: PCR primer name and specific sequence
Table 2 sgRNA sequence listing
Table 3: bottom strand oligonucleotide sequence of sgRNA
Detection kit (UCA) independently developed by using Baiosai chartTM) The sgRNA/Cas9 is subjected to activity detection, the activity detection result is shown in figure 3, and sgRNA5 and sgRNA8 are selected comprehensively from the sgRNA/Cas9 for subsequent experiments.
Next, CRISPR/Cas9 was transcribed in vitro, with the following specific steps:
1) preparing and obtaining a sgRNA forward oligonucleotide sequence and a reverse oligonucleotide sequence, wherein the forward oligonucleotide sequence and the reverse oligonucleotide sequence of sgRNA5 and sgRNA8 are respectively shown as SEQ ID NO.33-36, and the sequences are shown in Table 4;
2) synthesizing fragment DNA containing a T7 promoter and sgRNA scaffold, sequentially carrying out enzyme digestion on the fragments to be connected to a skeleton vector, and carrying out sequencing verification to obtain a plasmid vector (pT 7-sgRNA) with a T7 promoter;
3) the forward oligonucleotide and the reverse oligonucleotide described in step 1) were synthesized separately, and the synthesized sgRNA oligonucleotides were denatured and annealed to form a double strand (SEQ ID NO: 15-28);
4) linking the double-stranded sgRNA oligonucleotides annealed in the step 3) with pT7-sgRNA vectors respectively, screening to obtain sgRNA vectors, and carrying out in vitro transcription to obtain RNA for microinjection, wherein the result is shown in FIG. 17.
Table 4: sgRNA5 and sgRNA8 forward and reverse oligonucleotide sequences
Next, sgRNA5 and sgRNA8 are selected to design and construct a PHB1 gene conditional knockout targeting vector by selecting sgRNA/Cas9 target site sequence information, and a targeting strategy as shown in fig. 4 is designed, wherein the targeting vector contains a rat PHB1 gene homologous sequence, 2 loxp sequences, a3 'arm and a 5' arm, and sequentially comprises a5 'arm (SEQ ID No. 51), loxp, a PHB1 gene homologous sequence (E4, 5), loxp and a 3' arm (SEQ ID No. 52). Wherein, the loxP sites at the 5 'end and the 3' end are respectively inserted into intron3 and intron 5; the homology arms of the 5 'end and the 3' end are 1423bp and 1437bp respectively.
The construction of the targeting vector can be carried out by a conventional method, such as enzyme digestion connection, direct synthesis and the like. The constructed targeting vector is verified by enzyme digestion identification and sequencing, and the results are shown in FIG. 6, wherein 1-3 are positive clones. The correct targeting vector will be verified for subsequent experiments.
Mixing an in-vitro transcription product of a sgRNA vector, Cas9 mRNA and a targeting vector to obtain a mixed solution, injecting the mixed solution into cytoplasm or nucleus of rat fertilized eggs, transferring the injected fertilized eggs into a culture solution for culture, detecting and confirming the introduction condition of the targeting vector by utilizing a PCR technology, and screening correct positive clone cells, wherein a PCR integration detection primer is shown in Table 5:
table 5: loxp sequence insertion detection primer
The selected correct positive clone cells are transplanted into the oviduct of a receptor mother mouse to develop, and F0 generation rats, namely Flox rats, are obtained. The genotype of the F0 rat is detected, the used PCR primers are shown in Table 6, the result is shown in FIG. 7, and EK33-30, EK33-36, EK33-39, EK33-46, EK33-52 and EK33-54 are positive mice of F0 generation by PCR amplification and product sequencing. The F1 generation of rats was obtained by mating F0 generation positive rats with wild type rats, and the F1 generation rats were subjected to PCR identification and sequencing detection, wherein the PCR detection primers are shown in Table 6. As shown in FIG. 8, 1EK33-21, 1EK33-28, 1EK33-38, and 1EK33-41 were confirmed by PCR and sequencing to be positive conditioned knockout rats of F1 generation.
Table 6: f0 and F1 generation rat detection PCR primer name and specific sequence
PCR reaction conditions (Touchdown):
the Southern blot assay was performed on rats identified as positive by F1 PCR to confirm the presence of random insertions.
A schematic of the Southern blot screening strategy is shown in FIG. 5.
The specific design is as follows:
introducing Southern blot enzyme cutting sites outside the loxP sites at the 5 'end and the 3' end respectively, and if correct recombination occurs, two bands of a wild type and a mutant type can appear; if not recombined correctly, only wild-type bands will appear.
TABLE 7 length of the particular probes and target fragments
TABLE 8 Probe Synthesis primers
The lengths of the specific probes and the target fragments are shown in tables 7 and 8, the detection results are shown in FIG. 2, and 1EK33-21, 1EK33-28, 1EK33-38 and 1EK33-41 are positive rats of the F1 generation, and all have no random insertion.
Example 2 conditional PHB1 Gene knockout rats
In order to obtain a rat expressing Cre recombinase in choroid plexus tissues, specifically, a nucleotide sequence which is regulated by tamoxifen and encodes iCre-ERT2 is knocked into the downstream of a rat Adgra3 gene promoter by using a CRISPR/Cas9 system, and the Cre recombinase expression in a rat body is regulated by an Adgra3 gene regulation element, so that the rat specifically expresses Cre recombinase in the choroid plexus tissues.
The Flox heterozygote rat obtained in example 1 is crossed with a rat expressing Cre recombinase in choroid plexus tissue to realize the tissue-specific knockout of the target gene, and the specific scheme is shown in FIG. 9. WT is wild type rat, fl is F1 generation positive heterozygote rat obtained by mating F0 generation rat and wild type rat, and delta is tissue-specific or whole body knockout rat obtained by mating fl rat and tissue-specific Cre or Cre-deleter rat.
The first step is as follows: mating with tissue-specific Cre rats (Ts-Cre) to obtain fl heterozygous rats, as shown in fig. 10 or 11; wherein the genotype detection strategy is shown in table 9:
TABLE 9 conditional knockout rat first-step genotype detection strategy
Only heterozygote rats (fl/+, Cre/+) can be obtained in this step, and homozygote rats (experimental rats) need to be further mated for obtaining; rats with genotypes +/+, Cre/+, fl/+, +/+ can be used as controls.
The second step is that: obtaining fl homozygote rats, and crossing the heterozygote rats (fl/+, Cre/+) obtained in the previous step with each other to obtain homozygote rats (fl/fl, Cre/+) as shown in fig. 12, wherein the genotype testing strategy is shown in table 10:
TABLE 10 conditional knockout rat second step genotype detection strategy
Rats with the genotype fl/fl and Cre/+ belong to the experimental group (i.e., conditional knockout rats), and rats with other genotypes belong to the control group, preferably the control group is +/+, Cre/+ rats.
The primers used in this example are shown in Table 5.
Example 3PHB1 Whole Gene knockout rat (Whole body PHB1 knockout rat)
To obtain full knockout rats, fl heterozygous rats were mated with Cre-deleter rats, and the mating schedule is shown in FIG. 13. WT is wild type rat, fl is F1 generation positive heterozygote rat obtained by mating F0 generation rat and wild type rat, and delta is tissue-specific or whole body knockout rat obtained by mating fl rat and tissue-specific Cre or Cre-deleter rat.
The first step is as follows: mating with a Cre-deleter rat to obtain a full gene knockout heterozygote rat; the resulting F1 generation heterozygote rats were mated with Cre-deleter rats to remove Exon 4-5. The Cre-deleter rats used may be homozygotes or heterozygotes, as shown in FIG. 14. The genotype detection strategy is shown in table 11:
TABLE 11 first-step genotype detection strategy for full-knockout rats
Only heterozygote rats (delta/+, Cre/+) can be obtained in the step, and homozygote rats for experiments need to be further mated and obtained; rats with a genotype of +/+, Cre/+ can be used as controls.
The second step is that: whole gene knockout homozygous rats were obtained and heterozygous rats (Δ/+, Cre/+) were further mated as shown in FIG. 15. Wherein the genotype detection strategy is shown in table 12:
TABLE 12 second-step genotype detection strategy for full-knockout rats
Rats with a genotype of Δ/Δ belong to the experimental group (i.e., whole knockout rats), and rats with genotypes of Δ/+ and +/+ are the control group.
The primers used in this example are shown in Table 5.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
In addition, any combination of the various embodiments of the present invention is also possible, and the same should be considered as the disclosure of the present invention as long as it does not depart from the spirit of the present invention.
Sequence listing
<110> prevention and control center of diseases in Beijing
Construction method and application of PHB1 gene knock-out non-human animal
<130> 1
<160> 52
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
ctggtatatg tgctcgtgtc agg 23
<210> 2
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
ggtgaaactt cgtccatcca tgg 23
<210> 3
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ttagcttata cgttgtccaa agg 23
<210> 4
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
acatatacca gcccttagaa agg 23
<210> 5
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
tcaccagatc caagtaaccc agg 23
<210> 6
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
atccatggag tccactgacc tgg 23
<210> 7
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
gctaatgcca agaattctag agg 23
<210> 8
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
gggtcatagc gtccaacgga agg 23
<210> 9
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
gccatcagga atcacgttcc agg 23
<210> 10
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
gattcctcaa caaggggtcc tgg 23
<210> 11
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
tgatggctga ctgctcggcc tgg 23
<210> 12
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
ccctggaacg tgattcctga tgg 23
<210> 13
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
tctaaagtgg gtccagctca agg 23
<210> 14
<211> 23
<212> DNA/RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
ctcaaggatt cctcaacaag ggg 23
<210> 15
<211> 55
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
ctatttctag ctctaaaacg acacgagcac atataccggt gtttcgtcct ttcca 55
<210> 16
<211> 57
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
ctatttctag ctctaaaact ggatggacga agtttcaccg gtgtttcgtc ctttcca 57
<210> 17
<211> 55
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
ctatttctag ctctaaaact tggacaacgt ataagccggt gtttcgtcct ttcca 55
<210> 18
<211> 59
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
ctatttctag ctctaaaact tctaagggct ggtatatgtc cggtgtttcg tcctttcca 59
<210> 19
<211> 59
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
ctatttctag ctctaaaacg ggttacttgg atctggtgac cggtgtttcg tcctttcca 59
<210> 20
<211> 59
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
ctatttctag ctctaaaacg gtcagtggac tccatggatc cggtgtttcg tcctttcca 59
<210> 21
<211> 58
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 21
ctatttctag ctctaaaacc tagaattctt ggcattagcc ggtgtttcgt cctttcca 58
<210> 22
<211> 57
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 22
ctatttctag ctctaaaact ccgttggacg ctatgacccg gtgtttcgtc ctttcca 57
<210> 23
<211> 58
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 23
ctatttctag ctctaaaacg gaacgtgatt cctgatggcc ggtgtttcgt cctttcca 58
<210> 24
<211> 58
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 24
ctatttctag ctctaaaacg gaccccttgt tgaggaatcc ggtgtttcgt cctttcca 58
<210> 25
<211> 57
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 25
ctatttctag ctctaaaacg gccgagcagt cagccatccg gtgtttcgtc ctttcca 57
<210> 26
<211> 59
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 26
ctatttctag ctctaaaact caggaatcac gttccagggc cggtgtttcg tcctttcca 59
<210> 27
<211> 59
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 27
ctatttctag ctctaaaact gagctggacc cactttagac cggtgtttcg tcctttcca 59
<210> 28
<211> 59
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 28
ctatttctag ctctaaaacc ttgttgagga atccttgagc cggtgtttcg tcctttcca 59
<210> 29
<211> 43
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 29
gcatcaagct tggtaccgat gtctcatggc tgtgctaagt cgt 43
<210> 30
<211> 45
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 30
acttaatcgt ggaggatgat gctacatcta gttcctcagc agagc 45
<210> 31
<211> 45
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 31
gcatcaagct tggtaccgat cctcaggtct ctgtcactga acgtc 45
<210> 32
<211> 48
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 32
acttaatcgt ggaggatgat cacctcttag ctatggtctc ttgtggtc 48
<210> 33
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 33
taggtcacca gatccaagta accc 24
<210> 34
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 34
aaacgggtta cttggatctg gtga 24
<210> 35
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 35
tagggtcata gcgtccaacg ga 22
<210> 36
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 36
aaactccgtt ggacgctatg ac 22
<210> 37
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 37
taaacaacgg gaacatgtct gaggg 25
<210> 38
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 38
gcatgtgtgg acgaagggag ataat 25
<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 39
gagcgtccaa ccagatggca 20
<210> 40
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 40
catacaccag ggagaacagg c 21
<210> 41
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 41
ctgaggaggc tgagagaaag g 21
<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 42
cttgagaggc tggctcacac 20
<210> 43
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 43
tccccatttc tcctcatctc acaga 25
<210> 44
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 44
ctaagggctg gtatatgtgc tcgtg 25
<210> 45
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 45
attaatgtgg agctggggtc atagc 25
<210> 46
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 46
tcagagaatg gctgtttgaa cagc 24
<210> 47
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 47
tgaacacagg cagcaggata aatga 25
<210> 48
<211> 27
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 48
gacgcctaga ttgtgctact ctcagct 27
<210> 49
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 49
cgtgctagat cgactgctag agtgac 26
<210> 50
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 50
cacgctgagt tcacacctct gtatt 25
<210> 51
<211> 1423
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 51
gaatccagta ggcacgtgca cagtgcacac acttacatgt aggcaagaca ttgtacataa 60
aaagtaaggt gaatcttagg ggaaagttcc atgctgttct aactttgagg aactctaaag 120
tgtcttttgc tgctgtggtt aatccttccc atcagttcct ggtccccaga gtgactgtcc 180
aaactagtct ttggcagttt gtctctcctt gtggctgaca actttccctt tgccttgttt 240
tccacggtct ctgctccagc agggcagacc tcagactgcc ctctcacagg ctgcgccaca 300
cagccctgtg cctgagatat gccactggat ttctagttgg agcctgaagt gaccagccct 360
taccattccc ctccccagtc agtgaaggca gtaaagggag ctgactcgtg ggaagaagag 420
ggatcccgtg gggctcacgg cactcgatgc cctcagagct gttcctgggc agatgtttgc 480
tccttgtgct gtgcaggctt gctgccaggt tgaaggctcc tgtacaggga tgaccaaaaa 540
gagagctaac tattaaggac ctcagtcctc aggagggcaa gcatgagaac cggtaataga 600
gcaaggagaa gatggccagg ggcaagtgga gcagaggaga tctgcctgct ctccctagtg 660
ctgacctctt gattggagaa cctagagtga gaagtcaggt cagagaagag aagagaagag 720
gggaatagga agtctgcctg ccgctcctgc agaatgctgg gcctggcttg cctgctgcca 780
agaggaaata gaaggtgggg tggggtgatg gggatgagtg aggttggatt tagaatcctg 840
cttctaaacg tccgcctttg cgctttatat ccgtgttgtc tcatggctgt gctaagtcgt 900
atttgtacct gcacatgcta aaaattggga cgggcgattc tagtcatgaa tttcccactt 960
ctctcagtgg ctgggtcagg actccaaccc ctggcagccc ttagctgctg gtgctggcga 1020
acttacacag ggtggctgtg ccttagccct gcacgggcct ggattgtcag gagtaggtag 1080
gggctgactg tctccccaga tgcttgtgga caatgagtct tttgaattcg ccctgccttt 1140
ggcttaacgg cctttgtttt tagactttat cagaaatcct ctcacatcag cgtgctgtag 1200
tgccagctgc caccttctct caggtatcag gaagcaggcc ctggatggat gagccttagt 1260
ctactatcta tgagaaggtg ctgtccccat ttctcctcat ctcacagact aatacactca 1320
gtttgactaa gactggtccc caccattaga aaacagcaca gtggtaccac agcccaggtc 1380
agtggactcc atggatggac gaagtttcac cagatccaag taa 1423
<210> 52
<211> 1437
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 52
ggaaggcagt ataggaaata gagcatttca caccaaggcg aggggaaggg gtcgtgtttc 60
tagagtctct gggaaaagtc ttggagtgat ttgtcgggta acaaggcaga gtgcttcctg 120
ttctctctgc ggcctgcctg ggaaaggcta ggcttcccct cagcatctgc acagctgttc 180
aaacagccat tctctgagca acctctgctc ccctccaggc agggcctctt tcctccctcc 240
ctctctccgg ggaagggcat gtggctccct ctcctggcac tatgccaggc tgcagtcctt 300
gactctgcag cctgccttgc tccaggctct cccatgttaa cacagcactc tggcagtgag 360
aacacacgga gtaaaaacct gagagaaact tggcatcttt ctagactctg accacatact 420
ctatcctggg gaaatgtggc ctgaccacaa gagaccatag ctaagaggtg tgaggagaaa 480
attagatttc ctggggaatt tgctgccctc agctggccct ttcagaaaga aattttattc 540
tttaattaca catttagctt ttcagttctc aggattgtgt ttccaaatcc aaacttcaaa 600
tgagagtcca gagtgggtcc gacagagtag agcagcggca agataagatt tagctggcgt 660
atttggcaca cgcctggaat ggccgtgcgt atcagccctc ctgggctcag agtaagaccg 720
tcttagagca gaaacaagcc aaaagactta ggtctgtatt gtggaaaact cgggaggatg 780
tgtggtcaag atttttgcct gtacaaagca gagtttggga gggagcaggg gatgggggat 840
gaatgaagca aaattgcatt tgaacctaaa ttaacacctt tagaattttt tcctagactt 900
atattttttt tagctcgcat gtatgttttg tccgtgtttg taagggtgcc acgtgtgtgc 960
atcagatacc ctgtaactag agttagagat ggtttgaatc accatgtggc tgctaagcag 1020
caaacctggc cctttgcaag agcagccagg gctcctaagc actgagccct gtgcctgctc 1080
ttgcaataga aagatggact cagtgacttc ctgtaggctg ggccttagga gtgccaaggt 1140
ctgtccctct tctgtgctac ctcagagatc gtccctccag ccaaatactc gagctattta 1200
tgtgataggg aaggtctgtt gacagtcagg ctctcctgag caatggcttc acctgccttt 1260
cttttaaaac ctttaccaga actagtgtgt gtcagggatg ccatgatctg tgggccaccc 1320
tctgtcttcc tgtcaagggt ggaggtgctc tgagaaggaa gtgggctggt taatccataa 1380
gcagagaccg ccaggctcct ccatccctgg gaaccagctg catcccttgc tctcagg 1437
Claims (8)
1. A construction method of PHB1 gene knock-out non-human animal is characterized in that the construction method comprises knocking out No.4 to No.5 exons of PHB1 gene, so that PHB1 protein in choroid plexus tissue of the non-human animal is not expressed or the expressed PHB1 protein does not have function;
the construction method comprises the steps of inserting a homodromous specific recombination site recognition sequence into a No.3 intron and a No.5 intron of a non-human animal PHB1 gene respectively by using sgRNA to obtain a conditional PHB1 gene knockout Flox non-human animal, and introducing a recombinase or a recombinase expression sequence into the conditional PHB1 gene knockout Flox non-human animal; the target site sequence of the 5 'end of the sgRNA targeting is shown in SEQ ID NO.5, and the target site sequence of the 3' end of the sgRNA targeting is shown in SEQ ID NO. 8;
the non-human animal is a rat or a mouse.
2. The construction method of claim 1, wherein the construction method comprises inserting a LoxP or Frt sequence into intron3 and intron5 of PHB1 gene of non-human animal to obtain conditional PHB1 gene knockout Flox non-human animal, mating conditional PHB1 gene knockout Flox non-human animal with non-human animal expressing Cre or Flp recombinase in choroid plexus tissue, and knocking out PHB1 gene of non-human animal by Cre-LoxP or Flp-Frt gene recombination system.
3. The method according to claim 2, wherein the non-human animal expressing Cre or Flp recombinase in choroid plexus tissue is obtained by knocking a nucleotide sequence encoding Cre into a gene encoding a protein expressed from choroid plexus tissue.
4. The method of claim 1, comprising inserting a LoxP or Frt sequence into the PHB1 locus using sgRNA and/or targeting vectors,
the targeting vector comprises a5 'arm, a 3' arm and a donor DNA sequence, wherein the donor DNA sequence comprises a homodromous specific recombination site recognition sequence, a PHB1 gene nucleotide sequence and a homodromous specific recombination site recognition sequence from 5 'to 3'; wherein, the PHB1 gene nucleotide sequence comprises exons 4 to 5 of PHB1 gene, the 5 'arm is shown as SEQ ID NO.51, and the 3' arm is shown as SEQ ID NO. 52; the homotropic specific recombination site recognition sequence is LoxP or Frt.
5. A construction method of a conditional Flox non-human animal knocked out by a PHB1 gene is characterized in that a specific recombination site recognition sequence in the same direction is inserted into an intron3 and an intron5 of a non-human animal PHB1 gene by using sgRNA, the conditional Flox non-human animal knocked out by the PHB1 gene is obtained, a target site sequence at the 5 'end of the sgRNA targeting is shown as SEQ ID No.5, a target site sequence at the 3' end of the sgRNA targeting is shown as SEQ ID No.8, and the non-human animal is a rat or a mouse.
6. The sgRNA of a targeted non-human animal PHB1 gene is characterized in that a target site sequence at the 5 'end of the sgRNA is shown as SEQ ID No.5, a target site sequence at the 3' end of the sgRNA is shown as SEQ ID No.8, and the non-human animal is a rat or a mouse.
7. A targeting vector, characterized in that the targeting vector comprises a5 'arm, a 3' arm and a donor DNA sequence, wherein the donor DNA sequence comprises a specific recombination site recognition sequence in the same direction, a PHB1 gene nucleotide sequence and a specific recombination site recognition sequence in the same direction from 5 'to 3'; the nucleotide sequence of the PHB1 gene comprises exons 4 to 5 of the PHB1 gene, the 5 'arm is shown as SEQ ID NO.51, the 3' arm is shown as SEQ ID NO.52, and the homodromous specific recombination site recognition sequence is LoxP or Frt.
8. Use of the non-human animal obtained by the construction method according to any one of claims 1 to 5 or its progeny, the sgRNA according to claim 6, or the targeting vector according to claim 7 for studying the toxicological effects of heavy metals or other toxic substances on the choroid plexus of the brain and for preparing a medicament for treating or preventing obesity, diabetes, choroid plexus-related diseases, tumors, or inflammation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111663104.7A CN113999874B (en) | 2021-12-31 | 2021-12-31 | Construction method and application of PHB1 gene knock-out non-human animal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111663104.7A CN113999874B (en) | 2021-12-31 | 2021-12-31 | Construction method and application of PHB1 gene knock-out non-human animal |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113999874A CN113999874A (en) | 2022-02-01 |
CN113999874B true CN113999874B (en) | 2022-04-29 |
Family
ID=79932465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111663104.7A Active CN113999874B (en) | 2021-12-31 | 2021-12-31 | Construction method and application of PHB1 gene knock-out non-human animal |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113999874B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113999873B (en) * | 2021-12-31 | 2022-05-20 | 北京市疾病预防控制中心 | Construction method and application of genetically modified non-human animal |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080038227A1 (en) * | 2004-08-04 | 2008-02-14 | Ignacio Torres Aleman | Animal model of neurodegenerative diseases, the procedure for producing the model and applications thereof |
FR3007988B1 (en) * | 2013-07-04 | 2015-09-25 | Centre Nat Rech Scient | INHIBITION OF BETAAPP PROTEIN SYNTHESIS OR ABETA PEPTIDE ACTIVITY IN CHOROID PLEXUSES. |
-
2021
- 2021-12-31 CN CN202111663104.7A patent/CN113999874B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113999874A (en) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Friedman et al. | Thymic lymphomas in mice with a truncating mutation in Brca2 | |
Inoue et al. | Targeted disruption of the gene encoding the proteolipid subunit of mouse vacuolar H+-ATPase leads to early embryonic lethality | |
US20190352666A1 (en) | Genetically Modified Non-Human Animal With Human Or Chimeric OX40 | |
CN108531487B (en) | Preparation method and application of humanized SIRPA gene modified animal model | |
CN110438160B (en) | Construction method and application of Cd2ap gene knockout animal | |
CN109452229B (en) | Preparation method and application of caninized PD-1 gene modified animal model | |
CN111793647B (en) | Construction method and application of CD226 gene humanized non-human animal | |
CN113999874B (en) | Construction method and application of PHB1 gene knock-out non-human animal | |
CN107955817B (en) | Preparation method and application of humanized gene modified animal model | |
CN112501206B (en) | Construction method and application of PSMA (PSMA) gene humanized non-human animal | |
ES2209650B2 (en) | NON-HUMAN MAMMALS DEFICIENT MUTANTS IN SIGMA RECEIVERS AND THEIR APPLICATIONS. | |
US9295239B2 (en) | MO-1 conditional knock-out non-human animal and uses thereof | |
CN107974465B (en) | Slc6a13 gene and application of protein thereof | |
CN117384960B (en) | TL1A gene humanized non-human animal and construction method and application thereof | |
CN113388640B (en) | CCR4 gene humanized non-human animal and construction method and application thereof | |
WO2022222958A1 (en) | Genetically modified non-human animal with human or chimeric genes | |
CN115161326A (en) | SOST gene humanized non-human animal and construction method and application thereof | |
CN115873876A (en) | Construction method and application of FAP gene humanized non-human animal | |
CN115786354A (en) | Construction method and application of TGFB1, GARP and/or LRRC33 gene humanized non-human animal | |
CN115850442A (en) | Non-human animal humanized by TSLP and/or TSLPR gene and construction method and application thereof | |
US8946503B2 (en) | hnRNP A1 knockout animal model and use thereof | |
CN116463376A (en) | Construction method and application of BAFFR and/or BAFF gene humanized non-human animal | |
WAGNER et al. | Embryonic Stem Cells as | |
CN116420680A (en) | IGF1R gene humanized non-human animal and construction method and application thereof | |
CN112048522A (en) | Construction method and application of TMEM173 gene humanized and modified animal model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |